Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Talanta 212 , 120804 (2020)
Herlihy, A
Landmark Results The Phase 2 results, presented at the American Diabetes Association (ADA) Scientific Sessions in June 2023 and simultaneously published in the New England Journal of Medicine and The Lancet, were transformative: Weight loss : Up to 24.2% mean weight reduction at 48 weeks in the obesity trial (12 mg group), the highest ever reported for a pharmaceutical agent Glycemic control : Up to 2.02% HbA1c reduction in the diabetes trial, with most participants at higher doses achieving non-diabetic HbA1c levels Liver fat : Up to ~82% relative reduction in liver fat content Tolerability : GI adverse event profile consistent with the incretin class
For sleep, finish warm
Please note that shipments are not insured
doi:10.1056/NEJMoa2301972 PubMed: This landmark study demonstrated 24.2% mean weight loss at 48 weeks with the 12mg dose in 338 adults with obesity, establishing retatrutide as the most effective obesity medication tested to date
US$ 28.46
US$ 27.61
US$ 29.74
